SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
|
10803689 |
2000 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.
|
11457467 |
2001 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
|
17721742 |
2008 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis.
|
22496752 |
2012 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
|
8560407 |
1995 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been shown to be an independent risk factor for coronary artery disease.
|
9812921 |
1998 |
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, beneficial pleiotropic effects of statins on coronary artery disease may be attributable, in part, to attenuation of overexpression of PAI-1 mediated by the 3'-UTR in syndromes of insulin resistance (such as the metabolic syndrome) and type 2 diabetes.
|
20299979 |
2010 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial.
|
14629464 |
2003 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An insertion or deletion (I/D) polymorphism in the angiotensin converting enzyme (ACE) gene and a 4/5-guanine tract polymorphism (4G/5G) in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene are associated with the plasma activities of these substances and with coronary heart disease.
|
9844142 |
1998 |
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating (PAI-1) levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis.
|
9198234 |
1997 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined analyses of studies of the PAI-1 [-675] 4G variant yielded a per-allele relative risk for coronary disease of 1.06 (1.02-1.10), but there was an indication of publication bias in these studies.
|
16503463 |
2006 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors.
|
29494856 |
2018 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence suggested that the plasma levels of SERPINE1 modulate the risk of coronary artery disease; furthermore, that the 4G5G polymorphism affects the expression of the SERPINE1 gene.
|
20017074 |
2009 |
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Familial high PAI levels with concurrent hypofibrinolysis co-segregated with familial combined hyperlipidemia, both being independent risk factors for premature coronary heart disease.
|
8191398 |
1994 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analyses confirmed the effects of the PAI-1 gene-smoking interaction on CHD risk.
|
16424345 |
2006 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a sample of both 83 healthy individuals and 105 young patients with coronary artery disease from Sweden, the frequency of the 4G allele is roughly 0.5, and those individuals homozygous for the 4G allele have higher levels of PAI-1 than those with other genotypes (29% higher).
|
1456879 |
1992 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, HDL from CHD and ACS patients loses the ability of healthy HDL to suppress TF and to increase TFPI and t-PA and instead enhances PAI-1 and arterial thrombus formation.
|
25056722 |
2014 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In linkage analysis there was no evidence for a linkage of the ACE or PAI-1 loci with CHD.
|
11427204 |
2001 |
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the systematic meta-analysis, the highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age- and sex-adjusted model.
|
28550093 |
2017 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss two aspects of the molecular bases of CHD: i) Molecular bases of the candidate gene related to lipoprotein metabolism including apolipoprotein AI-CIII-AIV gene duster, apolipoprotein B, apolipoprotein E-CI-CII gene cluster, apolipoprotein(a), LDL receptors, lipoprotein lipase, cholesteryl ester transfer protein, and apo B editing protein; ii) Molecular bases of the candidate gene related to thrombotic and other factors including fibrinogen, factor VII, plasminogen activator inhibitor 1, homocysteine, stromelysin, paraoxonase, and angiotensin converting enzyme.
|
9539312 |
1998 |
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased plasminogen-activator inhibitor 1 (PAI-1) activity is a common finding in patients with coronary heart disease.
|
7892190 |
1995 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) concentration has been identified as a risk factor for coronary heart disease.
|
9445260 |
1998 |
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a <u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases.
|
30510136 |
2019 |
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease.
|
25501306 |
2015 |